Abstract:Therapeutics developed and sold as racemates can exhibit a limited therapeutic index because of side effects resulting from the undesired enantiomer (distomer) and/or its metabolites, which at times, forces researchers to abandon valuable scaffolds. Therefore, most chiral drugs are developed as single enantiomers. Unfortunately, the development of some chirally pure drug molecules is hampered by rapid in vivo racemization. The class of compounds known as immunomodulatory drugs derived from thalidomide is developed and sold as racemates because of racemization at the chiral center of the 3-aminoglutarimide moiety. Herein, we show that replacement of the exchangeable hydrogen at the chiral center with deuterium allows the stabilization and testing of individual enantiomers for two thalidomide analogs, including CC-122, a compound currently in human clinical trials for hematological cancers and solid tumors. Using "deuterium-enabled chiral switching" (DECS), in vitro antiinflammatory differences of up to 20-fold are observed between the deuterium-stabilized enantiomers. In vivo, the exposure is dramatically increased for each enantiomer while they retain similar pharmacokinetics. Furthermore, the single deuterated enantiomers related to CC-122 exhibit profoundly different in vivo responses in an NCI-H929 myeloma xenograft model. The (-)-deuterated enantiomer is antitumorigenic, whereas the (+)-deuterated enantiomer has little to no effect on tumor growth. The ability to stabilize and differentiate enantiomers by DECS opens up a vast window of opportunity to characterize the class effects of thalidomide analogs and improve on the therapeutic promise of other racemic compounds, including the development of safer therapeutics and the discovery of new mechanisms and clinical applications for existing therapeutics.

One-step synthesis of thalidomide and its important derivatives

Discovery of New Immunomodulatory Anticancer Thalidomide Analogs: Design, Synthesis, Biological Evaluation and In Silico Studies

A Two-Step, One-Pot, and Multigram-Scale Synthesis of N-Difluoromethylthiophthalimide

Synthesis and Biological Evaluation of Thalidomide Derivatives as Potential Anti-Psoriasis Agents

Investigation of N-hydroxythalidomide in vitro stability and comparison to other N-substituted derivatives

Electrochemical Behavior of Thalidomide

Multigram Synthesis of 3-Azabicyclo[3.1.1]heptane Derivatives Including Bicyclic Thalidomide Analogs

One-Step Synthesis of 1,3,4-Triaryl-substituted-3,4,5,6-tetrahydropyrimidin-2(1h)-one Derivatives

Determination of Thalidomide by High Performance Liquid Chromatography: Plasma Pharmacokinetic Studies in the Rat

Research Progress of Thalidomide in Usual Non-Hematologic Malignancies

Advances in Anti-Tumor Effect of Thalidomide

Exosome-Modified Liposomes Targeted Delivery of Thalidomide to Regulate Treg Cells for Antitumor Immunotherapy

Thalidomide: History of Research and Perspectives for Its Medical Use (Review)

Synthesis and Bioactivity of 2-Amino-5[(2-chloropyrid)-4-yl]-1,3,4-thiadiazole Derivatives

Photoinduced Decarboxylative Thioacylation of N‐Hydroxyphthalimide Esters with Tetraalkylthiuram Disulfides

Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogs

A Novel Approach to the Synthesis of 1,3,4-Thiadiazole-2-amine Derivatives

Understanding the Thalidomide Chirality in Biological Processes by the Self-disproportionation of Enantiomers

Synthesis of 2‐Substituted‐4,5‐Dihydrothiazol‐4‐Ols by [3 + 2] Annulation of 1,4‐Dithiane‐2,5‐Diol with Thioamides

Synthesis and spectral characteristics of N-(2,2,2-trichloro-1-((5-(R-amino)-1,3,4-thiadiazol-2-yl)amino)ethyl)carboxamides

Efficient One-Pot Synthesis of 2,4-Disubstituted Thiazoles and Dimeric Thiazoles Directly from Acyl Chlorides and β-Azido Disulfides